Asger B. L.
- Country
- Denmark
- Department
- Center for clinical metabolic research
Research Overview
- Repurposing colchicine for reduction of residual inflammatory risk in type 1 diabetes (REC1TE): a randomized, double-blind, placebo-controlled, investigator-initiated trial
- Evaluation of Orismilast and Semaglutide Combination Therapy on Body Weight Reduction in Obese Patients: A Randomized, Placebo-Controlled Trial
- Evaluation of the Efficacy and Safety of Cagrilintide and Semaglutide in Combination for Weight Reduction in Patients with Overweight or Obesity
Data & Insights
Has run more than one trial at 19 of 140 partner sites.
Specializations
Cardiovascular & Thrombotic Medicine
Focus on atherosclerotic cardiovascular disease. Investigation of heart failure across ejection‑fraction phenotypes. Evaluation of therapeutic strategies for atrial fibrillation. Emphasis on preventing major adverse cardiovascular events.
- inclisiran for ASCVD risk reduction
- colchicine for residual inflammatory risk
- asundexian versus apixaban in atrial fibrillation
- dapagliflozin effects on cardiac structure in CKD
- olezarsen for hypertriglyceridemia
Research spans primary and secondary prevention in high‑risk vascular populations.
Chronic Respiratory & Interstitial Lung Disease
Study of therapies for chronic obstructive pulmonary disease. Development of treatments for asthma in pediatric settings. Clinical evaluation of agents for progressive fibrosing interstitial lung diseases. Investigation of novel inhaled therapies for lung function preservation.
- azithromycin in pediatric asthma exacerbations
- inhaled treprostinil for PF‑ILDs
- BI 1015550 for fibrotic lung disease
- astegolimab for COPD exacerbations
- live vaccine training of innate immunity in COPD
Efforts aim to reduce exacerbations and slow disease progression.
Dermatology & Immune‑Mediated Skin Conditions
Targeted drug development for atopic dermatitis. Clinical assessment of agents for psoriasis and related disorders. Exploration of therapies for chronic spontaneous urticaria and hidradenitis suppurativa. Emphasis on systemic treatment options.
- upadacitinib for moderate‑to‑severe AD
- lebrikizumab in AD
- rocatinlimab in adolescent AD
- barzolvolimab for chronic spontaneous urticaria
- lutikizumab for hidradenitis suppurativa
Research integrates efficacy and safety endpoints in dermatologic populations.
Infectious Diseases & Antimicrobial Therapy
Clinical trials addressing acute respiratory infections. Evaluation of antiviral agents for COVID‑19. Investigation of immunoglobulin therapy for early SARS‑CoV‑2 infection. Optimization of antibiotic duration for serious bacterial infections.
- S‑217622 antiviral for COVID‑19
- hyperimmune immunoglobulin for early SARS‑CoV‑2 infection
- short‑course azithromycin for pediatric asthma‑like symptoms
- antibiotic duration studies in Gram‑negative bacteremia
- ExPEC9V vaccine for invasive E. coli disease
Focus remains on safety and efficacy in hospitalized adult cohorts.
Metabolism, Obesity & Diabetes
Investigations into agents that influence body weight. Studies of therapies for patients with type 2 diabetes at elevated cardiovascular risk. Evaluation of novel compounds for management of hypertriglyceridemia. Integration of metabolic and vascular outcomes.
- orismilast with semaglutide for obesity weight loss
- cagrisema for body weight reduction
- colchicine and low‑dose aspirin in type 2 diabetes cardiovascular outcomes
- MK‑0616 for major adverse cardiovascular events in high‑risk patients
- olezarsen for hypertriglyceridemia management
Research aligns metabolic control with cardiovascular benefit.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.